[pending] HALOPERIDOL DECANOATE (HALOPERIDOL DECANOATE)
Pending LLM rewrite. Source: FDA_DRUG D-0356-2025.
- Product
- HALOPERIDOL DECANOATE — HALOPERIDOL DECANOATE (HALOPERIDOL DECANOATE)
- Category
- Drug
- Distribution
- Distributed nationwide
Category
FDA recalls of prescription and over-the-counter drugs.
FDA drug recalls cover prescription medicines, over-the-counter products, biologic and gene therapies, and active pharmaceutical ingredients (the raw drug substances that manufacturers compound into finished products). Recall classifications follow the same Class I / II / III system as food, and most published recalls are Class II — the product is unlikely to cause permanent harm but doesn't meet specification.
The most common reasons for a drug recall are out-of-specification potency or dissolution (the active ingredient is present in too high or too low a dose), microbial contamination, particulate matter in injectables, mix-ups during packaging where bottles end up with the wrong tablets, and nitrosamine impurities in certain drug classes. Many drug recalls are at the lot level — the manufacturer's whole product line is still safe to use, but specific production lots are pulled.
If a recall affects your medication: don't stop taking it on your own. Call your prescriber or pharmacist before doing anything. Stopping a prescribed drug abruptly can be more dangerous than the issue prompting the recall. Most drug-recall remedies route through the dispensing pharmacy, who'll either swap your supply for an unaffected lot or coordinate a refund with the manufacturer.
Pending LLM rewrite. Source: FDA_DRUG D-0356-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0325-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0319-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0352-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0337-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0349-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0316-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0328-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0324-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0351-2025.
Glenmark Pharmaceuticals is recalling acetaminophen-ibuprofen tablets due to manufacturing quality deviations. No illnesses reported. Distributed nationwide via Amazon and Walmart.
Pending LLM rewrite. Source: FDA_DRUG D-0322-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0359-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0360-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0331-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0346-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0355-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0312-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0334-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0310-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0358-2025.
Glenmark Pharmaceuticals is recalling solifenacin succinate 10mg tablets nationwide due to manufacturing process deviations. The voluntary recall affects specific lot numbers distributed across the United States.
Glenmark Pharmaceuticals is voluntarily recalling Saxagliptin 5mg tablets nationwide due to CGMP deviations. Affected lot numbers are 17232460 and 17241194.
Glenmark Pharmaceuticals is recalling Saxagliptin 2.5mg tablets nationwide due to manufacturing quality issues. The firm initiated this voluntary recall on March 13, 2025.
Glenmark Pharmaceuticals is recalling Ranolazine Extended-Release 1000mg tablets (Lot 17240040) nationwide due to manufacturing deviations. This is a voluntary, firm-initiated recall.
Looking for a different category? Browse all recalls.